Troy Cox - 01 Sep 2021 Form 4 Insider Report for SomaLogic, Inc.

Role: Director
Signature: /s/ Brian Emes, Attorney-in-Fact for Troy Cox
Issuer symbol: N/A
Transactions as of: 01 Sep 2021
Net transactions value: +$500,000
Form type: 4
Filing time: 03 Sep 2021, 20:30:13 UTC
Previous filing: 07 May 2021
Next filing: 13 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLGC	Class A Common Stock	Other	$0	+25,000		$0.000000	25,000	01 Sep 2021	Direct	F1
transaction	SLGC	Class A Common Stock	Award	$500,000	+50,000	+200%	$10.00	75,000	01 Sep 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLGC	Warrants to purchase Class A Common Stock (right to buy)	Award		+166,666			166,666	01 Sep 2021	Class A Common Stock	166,666	$11.50	Direct	F2
transaction	SLGC	Class B Common Stock	Options Exercise	$0	-25,000	-100%	$0.000000^*	0	01 Sep 2021	Class A Common Stock	25,000		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
F2	Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination.

Content

In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination.